TY - JOUR
T1 - Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome
T2 - A randomized, controlled study
AU - Scolapio, J.
AU - Camilleri, M.
AU - Fleming, C. R.
AU - Oenning, L. V.
AU - Burton, D. D.
AU - Sebo, T. J.
AU - Batts, K. P.
AU - Kelly, D. G.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - Background and Aims: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The afro of this study was to compare effects of this treatment regimen and placebo in patients with short- bowel syndrome. Methods: A randomized, 6-week, double-blind, placebo- controlled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years) was performed. Active treatment was growth hormone (0.14 mg·kg-1·day-1), oral glutamine (0.63 g·kg-1·day-1), and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose absorption, morphology and DNA proliferation of small intestinal mucosa, and gastrointestinal transit were evaluated. Treatments were compared by paired t test. Results: Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. Conclusions: Although treatment with growth hormone, glutamine, and HCLF diet for 3 weeks resulted in modest improvements in electrolyte absorption and delayed gastric emptying, there were no improvements in small bowel morphology, stool losses, or macronutrient absorption.
AB - Background and Aims: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The afro of this study was to compare effects of this treatment regimen and placebo in patients with short- bowel syndrome. Methods: A randomized, 6-week, double-blind, placebo- controlled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years) was performed. Active treatment was growth hormone (0.14 mg·kg-1·day-1), oral glutamine (0.63 g·kg-1·day-1), and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose absorption, morphology and DNA proliferation of small intestinal mucosa, and gastrointestinal transit were evaluated. Treatments were compared by paired t test. Results: Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. Conclusions: Although treatment with growth hormone, glutamine, and HCLF diet for 3 weeks resulted in modest improvements in electrolyte absorption and delayed gastric emptying, there were no improvements in small bowel morphology, stool losses, or macronutrient absorption.
UR - http://www.scopus.com/inward/record.url?scp=0030856777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030856777&partnerID=8YFLogxK
U2 - 10.1053/gast.1997.v113.pm9322500
DO - 10.1053/gast.1997.v113.pm9322500
M3 - Article
C2 - 9322500
AN - SCOPUS:0030856777
SN - 0016-5085
VL - 113
SP - 1074
EP - 1081
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -